Get the tools and support you need to best manage your eczema

  • This field is for validation purposes and should be left unchanged.

Treatment

First Biologic Approved for Moderate to Severe Atopic Dermatitis

March 28, 2017 – Today, the U.S. Food and Drug Administration approved Dupixent (dupilumab), the first biologic medication for adults with moderate to severe atopic dermatitis (AD) for whom other topical treatments have not worked or are not advised. Different from topical or oral medications, biologic drugs or “biologics” are made from proteins typically derived […]

Read More


A potential lead for stopping staph in its tracks

March 21, 2017 – Our skin is covered in a web of billions of tiny organisms including bacteria, viruses and fungi. This web is called the skin microbiome and when healthy, helps our bodies function properly inside and out. Researchers have long known that people with atopic dermatitis (AD) have different skin biology than those […]

Read More


Each year, thousands of doctors, scientists, students, industry and patient advocacy groups like National Eczema Association, gather to hear the latest research and standards of medical care in dermatology at the American Academy of Dermatology (AAD) Annual Meeting. Atopic dermatitis is a hot field of study. Here’s some highlights from this year’s AAD meeting. Biologic […]

Read More


February 21, 2017 — There are dozens of new drugs in development for atopic dermatitis (AD). Late last year, the Food and Drug Administration (FDA) approved the non-steroidal topical treatment, Eucrisa for mild to moderate atopic dermatitis. This March, the FDA is expected to approve dupilumab, the first biologic drug for adults with moderate to […]

Read More


January 17, 2017 — Biologic drugs have been making headlines as potentially promising new therapies for treating atopic dermatitis (AD). Several have shown positive results in clinical trials and one, dupilumab, is being reviewed for approval by the Food and Drug Administration (FDA) and is expected to come to market in 2017. Biologic medications are […]

Read More


What is atopic dermatitis (AD)? AD is a severe form of eczema, which is an umbrella term used to describe a group of conditions that result in itchy, red, and irritated skin. It is a chronic, inflammatory disease that results in red, itchy patches on the skin that can crack and weep. AD falls into […]

Read More


December 20, 2016 — On December 14, the U.S. Food and Drug Administration approved Eucrisa (crisaborole), a topical treatment for children and adults with mild to moderate atopic dermatitis (AD). This marks the first new FDA-approved medication for atopic dermatitis in more than 10 years. “It’s a big deal because for at least 15 years, […]

Read More


December 14, 2016 — People with atopic dermatitis have a new treatment option. Today, the U.S. Food and Drug Administration approved Eucrisa (crisaborole), a topical treatment for children and adults with mild to moderate atopic dermatitis (AD). Eucrisa works differently than other topical treatments on the market. It is not a steroid or a topical […]

Read More


November 17, 2016 – For many years there were few treatment options available for people with eczema, including for those with a severe and chronic form of eczema, atopic dermatitis (AD). Today, there are more than 40 new therapies in development, some of which may come to market soon, and new clinical trials are getting underway on a regular basis. One […]

Read More


October 18, 2016 – For the first time in decades, new drugs and therapies that may provide real relief for anyone living with eczema are close to being available. For many, this is a time of unprecedented hope. But what if there were a way to prevent the very first flare, to stop eczema from even starting? Frustrated by […]

Read More